A Randomized, Double-blind, Placebo-controlled Study on the Efficacy and Safety of CVT-E002 in the Treatment of Upper Respiratory Tract Infections in a Pediatric (3-11 Years) Population
Summary
Parents with children aged 3-11 will participate in this study. About 400 children will take part in the study. We expect about half of those children will develop symptoms of a respiratory infection. This study will last about 6 months, during which time parents will be instructed to contact study staff if their child has symptoms of a respiratory infection. Those children who do meet the study criteria of symptoms will then be randomly placed (like a flip of a coin) into one of 2 groups to take either liquid COLD-fX® or placebo for 3 days. A placebo will look exactly like liquid COLD-fX® but contains no active ingredients. Your child has an equal chance of being placed in either of the above groups. Neither you nor the study staff will know which study group your child was placed in until the study is completed. If this information is needed in an emergency at any time throughout the study, it is quickly available from the sponsor.
Participation in the study will be for 14 days after symptoms of a respiratory infection are reported to study staff. Your child will take the study product for 3 days, you will complete a daily diary, receive 4 phone calls and be seen for a final study visit to review the diary and complete a final health check of your child.
Description
The primary objective is to assess the efficacy of acute dosing of CVT-E002 in reducing the duration of URTI symptoms in children 3-11 years of age.
The secondary objectives are to asses the efficacy of acute dosing of CVT-E002 in reducing: (1) symptom severity; (2) peak CARIFS scores and; (3) absenteeism for participant and/or parent/guardian. The ease of administration and the safety of acute dosing of CVT-E002 in children 3-11 years of age will also be assessed.
Study Design
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Upper Respiratory Tract Infections
Intervention
North American ginseng, Placebo
Location
Alberta Health Services
Edmonton
Alberta
Canada
T5N 4A3
Status
Recruiting
Source
Afexa Life Sciences Inc
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00965822
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-07-23T21:13:32-0400
Clinical Trials
Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.
This is a randomized double-blind three-arm trial to evaluate two dosages of CVT-E002 against placebo in pediatric upper respiratory tract infections (URTI). It is hypothesized that CVT-E...
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
The specific objectives of this investigation are to assess the effectiveness of daily gargling and vitamin D supplementation as preventative measures against incident upper respiratory tr...
Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
This randomized pilot trial studies how well North American ginseng extract AFX-2 (ginseng) works in decreasing cancer-related fatigue after treatment in cancer survivors. Ginseng may decr...
CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study
The purpose of this study is to assess the efficacy and safety of J022X ST for prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) compared to placebo in children of younger...
The purpose of the Study is to determine the prophylactic effects of CVT-E002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continui...
PubMed Articles
To investigate the effects of the recent upper respiratory tract infections (URI) on the incidence of perioperative respiratory adverse events in children scheduled to undergo general anesthesia and e...
Is the use of procalcitonin for guiding antibiotic decisions in patients with acute upper and lower respiratory tract infections associated with improved clinical outcomes compared with usual care?
Rhinovirus Viremia in Patients Hospitalized with Community Acquired Pneumonia.
Rhinoviruses (RVs) are ubiquitous respiratory pathogens that often cause mild or subclinical infections. Molecular detection of RV from the upper respiratory tract can be prolonged, complicating etiol...
Streptococcus pneumoniae commonly causes respiratory tract infections including acute otitis media and pneumonia. In this study, we evaluated the impact of general infant pneumococcal vaccination, int...
Excessive antimicrobial use for acute Upper Respiratory InfectionBackground Excessive antimicrobial use for acute Upper Respiratory Infections (URIs) is one of the most common problems in clinical pra...
Medical and Biotech [MESH] Definitions
Cefonicid
A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
Fusobacterium Nucleatum
A species of gram-negative, anaerobic, rod-shaped bacteria isolated from the gingival margin and sulcus and from infections of the upper respiratory tract and pleural cavity.
Coronavirus Nl63, Human
A species in the genus CORONAVIRUS causing upper and lower RESPIRATORY TRACT INFECTIONS. It shares the receptor used by the SARS VIRUS.
Indians, North American
Individual members of North American ethnic groups with ancient historic ancestral origins in Asia.
Aphthovirus
A genus of the family PICORNAVIRIDAE infecting mainly cloven-hoofed animals. They cause vesicular lesions and upper respiratory tract infections. FOOT AND MOUTH DISEASE VIRUS is the type species.
